FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response: 0							

Instruc	tion 1(b).			Filed							ities Exchang ompany Act o		of 1934			Lilouis	perio		0.5
1. Name and Address of Reporting Person* SHAH MAHENDRA					2. Issuer Name <b>and</b> Ticker or Trading Symbol Verona Pharma plc [ VRNA ]										licable)	ng Pe	Person(s) to Issuer		
(Last) (First) (Middle) 3 MORE LONDON RIVERSIDE					3. Date of Earliest Transaction (Month/Day/Year) 02/01/2021										Office below	er (give title		Other ( below)	specify
(Street) LONDO (City)								Li	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person										
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Y				n 2A. Deemed Execution Date,		е,	3. Transaction Code (Instr. 8) 4. Securities Ac Disposed Of (D			Acquire	ed (A) or tr. 3, 4 and	5. Amor Securiti Benefic Owned Reporte		ount of ties cially I Following	Fori	m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Ordinary Shares <sup>(1)</sup> 02/0:				02/01/20	21			S <sup>(2)</sup>	V	10,800	(D)	\$0.993	(Instr. 3 and 4		3 and 4)		D		
		Tal	ble I	l - Derivati (e.g., ρι							osed of, convertib				wne	d			
Derivative Conversion Da		3. Transaction Date (Month/Day/Year)	Exec if an	Deemed Lution Date, y y hth/Day/Year)	4. Transa Code ( 8)	(Instr.	of Deriv Secur Acqu (A) or Dispo	Expiration (Month/Espiration (			Exercisable and on Date Day/Year)		e and unt of rities rlying ative rity (Instr. 4)  Amount or Number of Shares	8. Pr Deri Seci (Inst		9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## **Explanation of Responses:**

1. Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Code

2. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of Restricted Stock Units.

3. The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from \$0.99375 to \$0.99625. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.

4. Consists of (i) 29,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 3,625 ADSs); and (ii) 54,760 Ordinary Shares represented by 6,845 ADSs.

> /s/ Claire Poll, Attorney-in-02/03/2021 fact for Mahendra Shah

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.